Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients
Authors:
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Clinical Radiology
- Vol. 73 (3) , 259-265
Abstract
No abstract availableKeywords
Funding Information
- Hunan Science and Technology Program
- Foundation for Distinguished Young Talents in Higher Education of Guangdong (2016KQNCX127)
This publication has 22 references indexed in Scilit:
- Chemoembolization for intermediate HCC: Is there proof of survival benefit?Journal of Hepatology, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virusJournal of Gastroenterology, 2010
- Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinomaHepatology International, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- X-TileClinical Cancer Research, 2004
- Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort studyBMJ, 2004
- Chemoembolization of Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000